New hope for pancreatic cancer: targeted drug combo enters human trials
Disease control
Not yet recruiting
This study tests a new biologic drug called ANO31905 combined with standard chemotherapy as a first treatment for people with advanced pancreatic cancer that has a specific marker (CLDN18.2). The trial has two phases: first to find a safe dose, then to see if the combination shri…
Phase: PHASE1, PHASE2 • Sponsor: Anova Innovation Limited • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC